About this trial

Shockwave TEVAR is a nonrandomized, prospective, international, multi-center, PMCF, obervational study.

The aim of this study is to evaluate the outcomes of the Shockwave™ Peripheral Intravascular Lithotripsy Balloon (Shockwave Medical Inc.) in the routine treatment of hostile iliac accesses during TEVAR and F/BEVAR.

Eligibility criteria

Qualifiers

Patient (m/f) age ≥ 18 years at time of enrollment.

Diagnosis of thoracic and/or thoraco-abdominal (Extent I-V) and juxta/para-renal/short-neck aneurysm requiring the implantation of a thoracic and/or thoraco-abdominal fenestrated/branched aortic endograft with delivery system introducer sheath diameter equal or larger than 18 Fr (6 mm).

Heavily circumferential calcified iliac arteries

Inner diameter ≤ 6 mm

Disqualifiers

Patients submitted to surgical conduit bypass.

Not-severely calcified disease (absence of calcification).

In-stent restenosis/occlusion.

Inability to cross with 0.014 guidewire.

Trial design

Treatments tested in this trial

  • Shockwave™ Peripheral Intravascular Lithotripsy Balloon M5+

Treatment groups

30 Participants
are divided into 1 treatment group

Locations

5
Germany
Department of Vascular Surgery, LMU Hospital Munich80337, MünichBavaria, Germany
Department of Vascular Surgery, Klinikum Nürnberg Campus Süd90471, NurembergBavaria, Germany
Italy
University of Genoa School of Medicine, Ospedale Policlinico San Martino - HSM16132, GenoaLiguria, Italy
Azienda Ospedaliera Universitaria Integrata di Verona37126, VeronaVeneto, Italy

Sponsors and collaborators

Rede Optimus Hospitalar SA

Lead sponsor

Shockwave Medical, Inc.

Collaborator